Introduction

The landscape of prostate cancer and its management has undergone significant changes over the past decade. Notably, there has been a decrease in the use of PSA screening since such testing was offered a Grade D recommendation by the United States Preventative Services Task Force (USPSTF) guidelines in late 2011.1 As a result, large observational database studies have suggested a relative decrease in incident prostate cancer and low-risk disease in the United States.1 There has also been a shift in management toward active surveillance for lower-risk disease and radical prostatectomy for higher-risk disease, seemingly at the expense of radiation.

Source: Seminars in Radiation Oncology - December 14, 2016 Category: Cancer & Oncology Authors: Jason A. Efstathiou Source Type: research